BioSpace News Archive

Sight Sciences, Inc. announced that Cigna Healthcare, has updated its Glaucoma Surgical Procedure policy to cover both ab interno canaloplasty and goniotomy procedures for the treatment of open-angle glaucoma effective June 15, 2023.

The prestigious scientific journal JAMA Neurology has published today the positive results from APRIL, the Phase 1b/2a clinical trial from aptaTargets,

The first European-funded CBE flagship for botanical extract manufacturing

NextCure, Inc. (Nasdaq: NXTC) today announced the presentation of a poster that defines the mechanism of NC525-induced apoptosis of leukemic cells, but not healthy hematopoietic cells, at the Federation of Clinical Immunology Societies (FOCIS) annual meeting in Boston.

Panbela Therapeutics, Inc. announced the closing of its previously announced public offering of 2,270,000 shares of its common stock or pre-funded warrants in lieu thereof and two classes of warrants to purchase up to an aggregate of 4,540,000 shares of its common stock at a purchase price of $3.75 per share and associated Public Warrants and $3.749 per pre-funded warrant and associated Public Warrants.

Aligos Therapeutics, Inc. (Nasdaq: ALGS) today announced that the company is presenting several posters collectively highlighting data from its liver disease programs at the European Association for the Study of the Liver (EASL) Congress 2023, taking place in Vienna, Austria, June 21 – 24, 2023.

Avid Bioservices, Inc. (NASDAQ:CDMO) today announced financial results for the fourth quarter and full fiscal year ended April 30, 2023.

Interius BioTherapeutics, a leading developer of in vivo cell-specific genetic medicine therapeutics, announced the presentation of compelling preclinical data at the Cellicon Valley 2023 Meeting in Philadelphia, PA.

Boston Pharmaceuticals announced positive Phase 2a results for BOS-580, its investigational, proprietary, long-acting fibroblast growth factor 21 analog for the treatment of non-alcoholic steatohepatitis.

Molecular Targeting Technologies, Inc. announced promising results from a 1-year follow-up on EBTATE treatment of gastroenteropancreatic neuroendocrine tumors without amino acid pretreatment.